Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Earnings for Ipca Laboratories Limited (IPCALAB.NS)
Earnings in 2023 (TTM): $99.8 M
According to Ipca Laboratories Limited's latest financial reports the company's current earnings (TTM) are $99.8 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ipca Laboratories Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $99.8 M | $64.82 M |
| 2022 | $88.26 M | $55.82 M |
| 2021 | $134.5 M | $104.7 M |
| 2020 | $163.59 M | $135.01 M |
| 2019 | $87.51 M | $71.81 M |
| 2018 | $64.72 M | $52.68 M |
| 2017 | $34.41 M | $28.35 M |
| 2016 | $32.01 M | $24.02 M |
| 2015 | $13.66 M | $11.46 M |
| 2014 | $42.76 M | $30.69 M |
| 2013 | $74.68 M | $56.63 M |
| 2012 | $53.8 M | $38.41 M |
| 2011 | $43.15 M | $32.81 M |
| 2010 | $40.35 M | $31.13 M |
| 2009 | $31.53 M | $24.32 M |
| 2008 | $14.01 M | $11.94 M |
| 2007 | $20.76 M | $16.1 M |
| 2006 | $18.27 M | $14.94 M |
| 2005 | $8.82 M | $7.28 M |
| 2004 | $11.15 M | $8.77 M |